- Home
- ACIU vs AIP Comparison
ACIU vs AIP Comparison
Compare ACIU & AIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- AIP
- Stock Information
- Founded
- ACIU 2003
- AIP 2003
- Country
- ACIU Switzerland
- AIP United States
- Employees
- ACIU N/A
- AIP N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- AIP Semiconductors
- Sector
- ACIU Health Care
- AIP Technology
- Exchange
- ACIU Nasdaq
- AIP Nasdaq
- Market Cap
- ACIU 332.4M
- AIP 277.9M
- IPO Year
- ACIU 2016
- AIP 2021
- Fundamental
- Price
- ACIU $3.15
- AIP $8.99
- Analyst Decision
- ACIU Strong Buy
- AIP Strong Buy
- Analyst Count
- ACIU 2
- AIP 4
- Target Price
- ACIU $12.00
- AIP $13.00
- AVG Volume (30 Days)
- ACIU 153.3K
- AIP 155.7K
- Earning Date
- ACIU 11-05-2024
- AIP 11-05-2024
- Dividend Yield
- ACIU N/A
- AIP N/A
- EPS Growth
- ACIU N/A
- AIP N/A
- EPS
- ACIU N/A
- AIP N/A
- Revenue
- ACIU $48,505,404.00
- AIP $54,739,000.00
- Revenue This Year
- ACIU $85.33
- AIP $8.13
- Revenue Next Year
- ACIU $80.69
- AIP $19.08
- P/E Ratio
- ACIU N/A
- AIP N/A
- Revenue Growth
- ACIU 4097200.00
- AIP 4.53
- 52 Week Low
- ACIU $2.25
- AIP $4.83
- 52 Week High
- ACIU $5.14
- AIP $9.54
- Technical
- Relative Strength Index (RSI)
- ACIU 45.68
- AIP 63.04
- Support Level
- ACIU $3.10
- AIP $8.28
- Resistance Level
- ACIU $3.25
- AIP $9.31
- Average True Range (ATR)
- ACIU 0.14
- AIP 0.42
- MACD
- ACIU -0.02
- AIP 0.04
- Stochastic Oscillator
- ACIU 13.16
- AIP 80.72
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About AIP Arteris Inc.
Arteris Inc is a developer of on-chip interconnect fabric technology designed for a variety of devices and in the development and distribution of Network-on-Chip (NoC) interconnect intellectual property (IP). The company's technology is used in System-on-Chip (SoC) and provides software and services to automate SoC integration, enabling users to efficiently deploy NoC IP, and offer IP support, maintenance services, professional services, and training and on-site support services. The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.